PROBLEM TO BE SOLVED: To provide the use for obtaining a pharmaceutical intended for a treatment of periventricular leukomalacia which is the most frequent cause of cerebral palsy in premature infants.SOLUTION: The use of agomelatine and its hydrates, crystalline forms and addition salts with a pharmaceutically acceptable acid or base is provided making use of the merits that agomelatine, or N-[2-(7-methoxy-1-naphthyl)ethyl]acetamide has a neuroprotective effect for promoting a repair mechanism of a secondary lesion of periventricular white matter and is therefore effective for the treatment of periventricular leukomalacia and moreover causes no problem of drug interactions.COPYRIGHT: (C)2008,JPO&INPIT【課題】未熟児における脳麻痺の最も高頻度の原因である脳室周囲白質軟化症の処置を目的とする医薬を得るための使用。【解決手段】アゴメラチンまたはN-[2-(7-メトキシ-1-ナフチル)エチル]アセトアミドが,脳室周囲白質の二次病巣の修復機序を促進するという神経防御効果を有し,脳室周囲白質軟化症治療に有効であり,しかも薬物相互作用の問題がないという特徴を有することによる,アンゴラメラチン,ならびにその水和物,結晶形,および薬学的に許容され得る酸または塩基との付加塩の使用。【選択図】なし
